PellePharm's Unattributed - III Round

PellePharm raised a round of funding on October 14, 2015.

PellePharm is developing topical patidegib, a first-in-class topical hedgehog inhibitor, to decrease the number of surgically-eligible basal cell carcinomas in Gorlin Syndrome patients.…

Articles about PellePharm's Unattributed - III Round: